Concentra Announces Preliminary Q4 2024 Revenue Of $465M, Up 5.5%, Net Income $20.6M-$22.6M; FY24 Revenue $1.9B, Up 3.4%, Net Income $169.7M-$171.7M; Q4 Adjusted EBITDA Up 13.6% To $77.5M; FY Adjusted EBITDA Up 4.3% To $376.9M; Patient Visits Down 2.1%; CapEx $18.1M In Q4
Benzinga
23 Jan
Fourth Quarter and Full Year 2024 Preliminary Results
For the fourth quarter 2024, Concentra expects to report:
Revenue of $465.0 million, an increase of 5.5% over Q4 2023
Net income in the range of $20.6 million to $22.6 million, compared to $28.9 million in Q4 2023
Adjusted EBITDA of $77.5 million, an increase of 13.6% over Q4 2023
Patient Visits of 2,994,988, or 46,797 Visits per Day, a decrease in Visits per Day of 2.1% from Q4 2023
Revenue per Visit of $145.08, an increase of 5.8% over Q4 2023
Capital Expenditures of $18.1 million, compared to $23.6 million in Q4 2023
Total occupational health centers of 552, compared to 544 at end of Q4 2023
Total onsite health clinics of 157, compared to 150 at end of Q4 2023
For full year 2024, Concentra expects to report:
Revenue of $1,900.2 million, an increase of 3.4% over FY 2023
Net income in the range of $169.7 million to $171.7 million, compared to $184.7 million in FY 2023
Adjusted EBITDA of $376.9 million, an increase of 4.3% over FY 2023
Cash balance of $183.3 million and net leverage ratio of approximately 3.5x
Patient Visits of 12,623,503, or 49,311 Visits per Day in the quarter, a decrease in Visits per Day of 2.0% from FY 2023
Revenue per Visit of $141.30, an increase of 4.5% over FY 2023
Capital Expenditures of $65.7 million, compared to $65.0 million in FY 2023
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.